Liraglutide
Also known as: Victoza, Saxenda
Classification
Pharmaceutical
Regulatory Status
FDA-approved prescription product
Sources
16
Review
n/a
Overview
Liraglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist analog used in the management of type 2 diabetes mellitus, prevention of cardiovascular complications associated with diabetes, and obesity.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Liraglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist analog used in the management of type 2 diabetes mellitus, prevention of cardiovascular complications associated with diabetes, and obesity.
Benefits
People look up liraglutide for type 2 diabetes, cardiovascular risk reduction in eligible adults with T2D, and chronic weight management under Saxenda labeling; these are prescription uses with boxed warnings.
Interactions & cautions
Drug interactions
insulin or insulin secretagogues — Increased hypoglycemia risk — label advises dose consideration of concomitant agents (review)
These are observational flags for review, not individualized instructions.
Sources
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4 (opens in a new tab)
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143 (opens in a new tab)
- https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize (opens in a new tab)
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw